dc.creator | Bellei, Mónica | |
dc.creator | Foss, Francine M. | |
dc.creator | Shustov, Andrei | |
dc.creator | Horwitz, Steven M. | |
dc.creator | Marcheselli, Luigi | |
dc.creator | Kim, Won Seog | |
dc.creator | Cabrera, María Elena | |
dc.creator | Dlouhy, Iván | |
dc.creator | Nagler, Arnon | |
dc.creator | Advani, Ranjana H. | |
dc.creator | Pesce, Emanuela Anna | |
dc.creator | Ko, Young-Hyeh | |
dc.creator | Martínez, Virginia | |
dc.creator | Montoto, Silvia | |
dc.creator | Chiattone, Carlos | |
dc.creator | Moskowitz, Alison | |
dc.creator | Spina, Michele | |
dc.creator | Biasoli, Irene | |
dc.creator | Manni, Martina | |
dc.creator | Federico, Massimo | |
dc.date.accessioned | 2018-12-27T19:39:34Z | |
dc.date.available | 2018-12-27T19:39:34Z | |
dc.date.created | 2018-12-27T19:39:34Z | |
dc.date.issued | 2018-07-03 | |
dc.identifier | Haematologica, 103(7), 03 julio 2018, 1191-1197 pp. | |
dc.identifier | 0390-6078 | |
dc.identifier | 10.3324/haematol.2017.186577 | |
dc.identifier | http://repositorio.uchile.cl/handle/2250/159232 | |
dc.description.abstract | This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation. | |
dc.language | en | |
dc.publisher | Ferrata Storti Foundation | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
dc.source | Haematologica | |
dc.subject | non-hodgkins-lymphomas | |
dc.subject | response criteria | |
dc.subject | classification | |
dc.subject | survival | |
dc.title | The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project | |
dc.type | Artículos de revistas | |